David Ancona-Lezama, MD

Contact information
LOCATION

• Hospital Zambrano Hellion
  Batallon de San Patricio 112, Instituto de Oncología, Monterrey, 66278
  +51 81 2622 2188
  Map and directions »

LINKEDIN
https://www.linkedin.com/in/david-ancona-lezama-76b033118/

WEBSITE
https://www.topdoctors.mx/doctor/david-ancona-lezama#

SPECIALTY
Ophthalmic Oncologist

Education and Fellowships
BOARD CERTIFICATIONS
Consejo Mexicano de Oftalmologia
BOARD CERTIFICATIONS
Asociacion Para Evitar la Ceguera
FELLOWSHIP
Wills Eye Hospital

Current Positions
Professor of Ophthalmology
Ocular Oncology Department
Retina Department

Biography​
Dr. David Ancona is a Mexican ophthalmologist trained in Retina Surgery at Asociacion Para Evitar la Ceguera (Mexico City, Mexico) and in Ocular Oncology at Wills Eye Hospital (Philadelphia, USA) under the mentorship of Dr. Carol Shields and Dr. Jerry Shields. He is currently Professor of Ophthalmology at Tecnologico de Monterrey, one of Mexico's top 2 Universities

---

Selected publications
​

• Combination of multimodal imaging features predictive of choroidal nevus transformation into melanoma.
  Six risk factors for choroidal nevus transformation into melanoma by multimodal imaging have been identified. Risk for transformation into melanoma is 1% when no factors are present, and approaches 100% with specific combinations of three or more risk factors.
• OPHTHALMIC VASCULAR EVENTS AFTER INTRA-ARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: Real-World Comparison Between Primary and Secondary Treatments.
  Ophthalmic vascular events after IAC for retinoblastoma affect only 5% of eyes per infusion (17% of treated eyes). Vascular event risk per eye is similar when using IAC as primary or secondary treatment.
• Ophthalmic Vascular Events after Primary Unilateral Intra-arterial Chemotherapy for Retinoblastoma in Early and Recent Eras.
  Ophthalmic vascular events after IAC have decreased from the early era (2009-2011) through the current era (2012-2017) at this center. Experience performing this highly specialized procedure could be an important factor predicting IAC-related vascular events.
• The unusual association of inverse retinitis pigmentosa and Fuchs' heterochromic iridocyclitis.
  Patients with RP are prone to develop chronic, low grade inflammation responses similar to the ones present in FHI. It also suggests FHI may be a triggered response predisposed by an unidentified genetic factor that may be related to genes affected in RP and thus be identified before irreversible complications such as glaucoma occur.
• Bilateral Ocular Decompression Retinopathy after Ahmed Valve Implantation for Uveitic Glaucoma.
  Ocular decompression retinopathy is a rare complication of filtering surgery in patients with glaucoma; however, the course is benign in most cases, with spontaneous resolution of bleedings and improvement of visual acuity.
• Contralateral Autologous Corneal Transplantation Experience in Mexico City.
  Autokeratoplasty is a good choice in cases having high risk factors and when fresh corneal tissue is not available. This is the largest study describing outcomes of patients who underwent autokeratoplasty. This study reports a good prognosis in cases having high risk factors for failure.
• Effects of topical travoprost 0.004% on intraocular pressure and corneal biomechanical properties in an animal model.
  Post-treatment reduction of IOP in treated eyes was a direct hypotensive effect of travoprost 0.004% and was not affected by changes in corneal biomechanics properties (CH and CRF), resulting in real lower IOP values.​